title: [Effects of autologous plasma and gentamicin on immunophenotype and viability of cytokine-induced killer cells].
abstract: OBJECTIVE
  To investigate the effects of treatment with different volumes of autologous plasma and gentamicin on immunophenotype and viability of cytokine-induced killer (CIK) cells in vitro.
  
  
  METHODS
  Flow cytometry (FCM) was used to analyze the effects of autologous plasma and gentamicin on different immunocyte subtypes of CIK cells. The cell count method and MTT assay were used to detect the cytotoxicity of such pretreated CIK cells on HeLa cells.
  
  
  RESULTS
  No significance was found in the relative amount of immunocyte subtypes CD3(+), CD56(+), CD3(+)CD4(+), CD3(+)CD8(+), CD3(+)CD56(+), CD4(+)CD25(+) between autologous plasma and control groups. Compared with control group, CD3(+), CD56(+), CD3(+)CD8(+), CD3(+)CD56(+) cells of gentamicin group were significantly down-regulated by 1.4, 1.7, 1.4 and 2.5 folds (P<0.05), respectively. Furthermore, the cytotoxicity of CIK cells in gentamicin and control groups on HeLa cells were 43.0% and 90.0%, respectively, with a statistically significant difference (P<0.05).
  
  
  CONCLUSIONS
  Autologous plasma has little effect on different subtypes of CIK cells. On the contrary, gentamicin can cause a decrease in the number of CD3(+), CD56(+), CD3(+)CD8(+), CD3(+)CD56(+) cells with some cytotoxicity.
authors.affiliation: Shenzhen Hornetcorn Bio-technology Company, Hengyang 421001, China.
authors.forename: Jingsong
authors.initials: J
authors.lastname: Cao
authors.affiliation: Institute of Clinical and Biological Cell Therapy, Second Affiliated Hospital, University of South China, Hengyang 421001, China.
authors.forename: Weiguo
authors.initials: W
authors.lastname: Yin
authors.affiliation: Department of Clinical Laboratory, Second Affiliated Hospital, University of South China, Hengyang 421001, China.
authors.forename: Cong
authors.initials: C
authors.lastname: Chen
authors.affiliation: Shenzhen Hornetcorn Bio-technology Company, Hengyang 421001, China.
authors.forename: Xiaoling
authors.initials: X
authors.lastname: Luo
mesh_terms: D017252:CD3 Complex / Q000378:metabolism; D015704:CD4 Antigens / Q000378:metabolism; D019002:CD56 Antigen / Q000378:metabolism; D016827:CD8 Antigens / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects / Q000276:immunology; D002478:Cells, Cultured; D055612:Cytokine-Induced Killer Cells / Q000276:immunology* / Q000378:metabolism; D003602:Cytotoxicity, Immunologic / Q000187:drug effects / Q000276:immunology; D005434:Flow Cytometry; D005839:Gentamicins / Q000276:immunology* / Q000494:pharmacology; D006367:HeLa Cells; D006801:Humans; D016130:Immunophenotyping / Q000379:methods*; D053645:Interleukin-2 Receptor alpha Subunit / Q000378:metabolism; D007958:Leukocyte Count; D010949:Plasma / Q000276:immunology*; D011500:Protein Synthesis Inhibitors / Q000276:immunology / Q000494:pharmacology
chemical_list: D017252:CD3 Complex; D015704:CD4 Antigens; D019002:CD56 Antigen; D016827:CD8 Antigens; D005839:Gentamicins; D053645:Interleukin-2 Receptor alpha Subunit; D011500:Protein Synthesis Inhibitors